Pay for outcomes, not treatments
Family building benefits for everyone, including IVF, egg freezing, shared motherhood, surrogacy, and adoption
40% of your employees are currently exploring their path to parenthood. Here’s why you should invest in family building.
It’s bigger than you think
It’s disrupting your business
…and you’re already paying for it
Introducing Gaia: the world’s first Value-Based Family Building benefit
Value-Based Family Building means you only pay for live births, not procedures. Perfectly aligned incentives mean everybody wins: employers get a much higher ROI on their benefit dollars, employees get optimized treatment pathways to parenthood, and Gaia gets rewarded for delivering the best, most efficient care possible.
Maximize your ROI
Fertility treatment outcomes aren't guaranteed. By paying for outcomes, not procedures, every dollar goes toward a positive outcome, reducing your overall cost per employee. Gaia pays for the journeys that don’t go to plan.
Offer efficient and equitable benefits
Each employee gets access to the personalized treatments they need to maximize their chances of a live birth — not an ineffective, one-size-fits-all allocation.
Ensure quality care
When you pay for outcomes, you incentivize providers to offer high quality care and the most efficient treatment pathways, saving money compared to other fertility benefits and producing more positive outcomes.
With you every step of the way
Concierge support at every step, plus ongoing education and engagement from experts (90+ NPS and CSAT)
Vetted partner clinics with 90% single embryo transfer rate, to ensure you don’t introduce unnecessary risks to pregnancies and deliveries
Inclusive, equitable benefits for everyone: egg freezing, shared motherhood, surrogacy, and adoption
Meet the team
15 years in finance.
Ex Goldman Sachs.
4 years of IVF.
15 years in marketing.
Ex Ladder Life, Dropbox, Thumbtack.
10 years in healthcare
Ex Sword, Virta, McKinsey, US Navy.
8 years in product and partnerships
Ex babylon health, Hey Jane, HBS.
Backed by top investors
